Opioid Review and MAT Clinic- Diversion

Size: px
Start display at page:

Download "Opioid Review and MAT Clinic- Diversion"

Transcription

1 1 Opioid Review and MAT Clinic- November 14, 2018

2 2 Announcements

3 Announcements CME evaluation forms are due to Katie Stangl by Friday, Nov. 16 th at 4:00pm. 3

4 Upcoming Presentations November 21: No ECHO next week! November 28: Children's Hospital presenting an Overview of Neonatal Abstinence Syndrome December 5: Dr. Charlie Reznikoff, Addiction Medicine at Hennepin Healthcare presenting on Benzodiazepine Withdrawal: Assessment and Tapers 4

5 Upcoming Presentations December 12 th : Hon. Marta Chou, Minnesota Fourth Judicial District December 19 th : Dr. Sanjeev Arora, founder of Project ECHO, presenting on Hepatitis C and IV Drug Use January 23 rd : Dr. Wilson Compton, MD, PhD, Deputy Director, National Institute on Drug Abuse 5

6 Buprenorphine Providers? If you or someone within you clinic is considering or will be starting to prescribe buprenorphine, please private message Katie. We would love to help in any way possible! If you are interested in participating in a specific nurse or physician meeting related to MAT and/or bup, please Katie and let her know 6

7 Missed a Session? If you have missed a session and wish to watch it, just Katie and she will send you the link to watch! 7

8 Outcomes Evaluate the many causes of prescription diversion Identify the different characteristics of individuals who divert medications 8

9 Multiple determinants of specific modes of prescription diversion (2011). 9

10 This paper examines sources of diverted drugs from 2 larges studies and characteristics of patients National sample of opioid treatment patients, N=1983 Florida sample of treatment patients, N=782 10

11 National Sample Florida Sample Age Sex M=F Ethnicity 82% Caucasian 56% Caucasian Income 70%<25,000 Mod/Severe Pain 59.2% 63% 11

12 Older patients and noninjectors Avoid dealers and theft More likely to see physicians, legit or not 12

13 Those with higher income or/and insurance were more likely to see a physician whether legit, or not Those with <$10,000 income more likely to have a dealer, share and steal meds 13

14 Female 48 years old Pain pills for double mastectomy 14

15 Women Less likely to use dealer More likely to see physician, legit or not More often share or trade Occasional theft 15

16 Male 23 years old Full time National Guard 16

17 Age year olds- more likely to use dealer and obtain through theft >45 years old- 3x less likely to use dealer 17

18 Female 25 years old Injecting prescription drugs 18

19 Patients who injected opioids were more likely to have a dealer 19

20 Female 43 years old History of Crohn s disease 20

21 When patients use a medical source to get medication they are misusing they are 2x more likely to have: Insurance Health problems Reported mod/severe pain in last 90 days 21

22 Male 34 years old Engineer at a refinery $60,000 in debt with dealer 22

23 Drug type Those who misused Oxy ER were more likely to get from a dealer (2x more than prescriber) 23

24 Female 42 years old Business owner 20 year history of receiving Norco for fibromyalgia 24

25 Drug type Those who misused hydrocodone were more likely to get from a prescriber Those who misuse methadone more often get from a prescriber 25

26 Female 30 years old Pharmacy technician 26

27 Theft of opioids Younger Twice as likely to be white IV user 3x as likely to steal meds Those that misuse oxycodone 27

28 Female Previous opioid use disorder diagnosis Being tapered off benzo 28

29 Veterinary 13% are aware of animals that were intentional injured to get pain medication 12% were aware of staff opioid abuse and diversion Vet office do not use pharmacies, there is NO requirement to log into state PDMP 29

30 30

31 31

32 32

33 Elderly as a source of opioids Added income to social security Sell to family and friends Unaware of consequences 33

34 34

35 Distance 35

36 How do we help decrease diversion? Provide appropriate treatment and prescribing to chronic pain patients Screen for opioid use disorder Urine screen (sometimes witnessed) to help identify patients who are diverting or have other substance use disorders 36

37 Resources The New Opioid Dealers. Eaton, Joe. June Multiple determinants of specific modes of prescription opioid diversion. Cicero TJ, Kurtz SP, Surratt HL, Ibanez GE, Ellis MS, Levi-Minzi MA, Inciardi JA. J Drug Issues Spring;41(2): The source and diversion of pharmaceutical drugs for non-medical use: A systematic review and meta-analysis. Hulme S, Bright D, Nielsen S. Drug Alcohol Depend May 1;186: doi: /j.drugalcdep Epub 2018 Mar 27. Outbreaks of Infections Associated With Drug by US Health Care Personnel. Schaefer, Melissa, MD., Perz, Joseph, DrPH. Mayo Clinic Proceedings, , Volume 89, Issue 7, Pages , Copyright 2014 The High Cost of Drug. Lindsay, Erica, PharmD., Pharmacy Times, 2016 January 3. Prescription Opioid Epidemic: Do Veterinarians Have a Dog in the Fight? Mason DS, Tenney L, Hellyer PW, Newman LS. Am J Public Health Sep;108(9): doi: /AJPH

Medical vs. Use of Drugs. Warning Signs of Chemical Dependence. Intent Effect. Legality Pattern 5/5/2010. Daily use above ceiling doses

Medical vs. Use of Drugs. Warning Signs of Chemical Dependence. Intent Effect. Legality Pattern 5/5/2010. Daily use above ceiling doses Identifying and Preventing Drug Abuse By: Lon R. Hays, M.D., M.B.A. Professor and Chairman Department of Psychiatry University of Kentucky Healthcare Medical vs. Non-Medical Use of Drugs Intent Effect

More information

A Rural Primary Care Clinic s Successful Response to the Opioid Epidemic. Dr. Kurt DeVine Dr. Heather Bell

A Rural Primary Care Clinic s Successful Response to the Opioid Epidemic. Dr. Kurt DeVine Dr. Heather Bell A Rural Primary Care Clinic s Successful Response to the Opioid Epidemic Dr. Kurt DeVine Dr. Heather Bell A Call to Action / 3 A Call to Action The number of emergency room visits attributable to pharmaceuticals

More information

The Use of Qualitative Research in Large Quantitative Studies: Capturing the Subtleties

The Use of Qualitative Research in Large Quantitative Studies: Capturing the Subtleties The Use of Qualitative Research in Large Quantitative Studies: Capturing the Subtleties MARIA A. LEVI-MINZI, M.A., HILARY L. SURRATT, PH.D., STEVEN P. KURTZ, PH.D. THE QUALITATIVE REPORT 6 TH ANNUAL CONFERENCE

More information

Article #2 Prescription Drug Overdose CDC: Centers for Disease Control and Prevention. Understanding the Epidemic

Article #2 Prescription Drug Overdose CDC: Centers for Disease Control and Prevention. Understanding the Epidemic Article #2 Prescription Drug Overdose CDC: Centers for Disease Control and Prevention Understanding the Epidemic When the Prescription Becomes the Problem In a period of nine months, a tiny Kentucky county

More information

Gabapentin diversion and misuse in the United States from a law enforcement perspective: Diversion rates and qualitative research findings

Gabapentin diversion and misuse in the United States from a law enforcement perspective: Diversion rates and qualitative research findings Gabapentin diversion and misuse in the United States from a law enforcement perspective: Diversion rates 2002-2015 and qualitative research findings Mance E. Buttram, PhD Steven P. Kurtz, PhD 2 nd European

More information

Gabapentin diversion and misuse: Data from law enforcement and substance users

Gabapentin diversion and misuse: Data from law enforcement and substance users Gabapentin diversion and misuse: Data from law enforcement and substance users Mance E. Buttram, PhD NDEWS Presents Webinar 14 March 2018 Objectives 1. Brief overview of gabapentin literature 2. Present

More information

Opioid Focus Group Summaries

Opioid Focus Group Summaries Opioid Focus Group Summaries In 2018, the Snohomish Health District held a series of roundtable discussions with providers and prescribers to better understand how they see the opioid epidemic unfolding,

More information

Buprenorphine & Controlled Substance Treatment Agreement

Buprenorphine & Controlled Substance Treatment Agreement Buprenorphine & Controlled Substance Treatment Agreement I agree to accept the following treatment contract for buprenorphine office-based opioid addiction treatment: 1. I will keep my medication in a

More information

What is drug diversion?

What is drug diversion? Learning Objectives Identify the impact of drug diversion on patients and healthcare organizations Explain the common points of risks and methods of drug diversion in healthcare s controlled substance

More information

NYSHFA/NYSCAL 16 th Annual Nurse Leadership Conference. Timothy J. Dewey Sr. Investigator NYS Bureau of Narcotic Enforcement.

NYSHFA/NYSCAL 16 th Annual Nurse Leadership Conference. Timothy J. Dewey Sr. Investigator NYS Bureau of Narcotic Enforcement. NYSHFA/NYSCAL 16 th Annual Nurse Leadership Conference Timothy J. Dewey Sr. Investigator NYS Bureau of Narcotic Enforcement May 2, 2018 1 May 2, 2018 2 Bureau Overview May 2, 2018 3 HISTORY 1850--Bureau

More information

Talking about SBIRT for adolescents: An upstream intervention to address the heroin and prescription opioid epidemic

Talking about SBIRT for adolescents: An upstream intervention to address the heroin and prescription opioid epidemic Talking about SBIRT for adolescents: An upstream intervention to address the heroin and prescription opioid epidemic Brett R. Harris, DrPH University at Albany School of Public Health Drug Overdose is

More information

CDC s Efforts to End the Opioid Epidemic

CDC s Efforts to End the Opioid Epidemic Amy Insert Peeples, CIO Name MPA Here Deputy Director, National Center for Injury Prevention and Control NCSL Opioid Policy Fellows Kick Off CDC s Efforts to End the Opioid Epidemic The Epidemic in America

More information

Vermont Hub and Spoke Model Treatment Need Questionnaire

Vermont Hub and Spoke Model Treatment Need Questionnaire Vermont Hub and Spoke Model Treatment Need Questionnaire Friday, June 30, 2017 John Brooklyn, MD Assistant Professor of Family Medicine and Psychiatry University of Vermont Burlington, Vermont Webinar

More information

Opioid Addiction Statistics

Opioid Addiction Statistics May 2017 Opioid Addiction Statistics Definitions Heroin Epidemic - As pill mills close, prescribing is becoming tighter, demand among younger users rise, and dealer s profits rise, addicts are turning

More information

NBPDP Drug Utilization Review Process Update

NBPDP Drug Utilization Review Process Update Bulletin # 802 December 1, 2010 NBPDP Drug Utilization Review Process Update The New Brunswick Prescription Drug Program (NBPDP) employs a Drug Utilization Review (DUR) process which identifies, investigates

More information

TREATING OPIOID ADDICTION IN HOMELESS POPULATIONS

TREATING OPIOID ADDICTION IN HOMELESS POPULATIONS TREATING OPIOID ADDICTION IN HOMELESS POPULATIONS Challenges and Opportunities Providing Medication Assisted Treatment (Buprenorphine) August 18, 2016 SPEAKERS TODAY Nilesh Kalyanaraman, MD, Chief Health

More information

Substance Use Disorders (SUDs) and Medication Assisted Treatment (MAT) for Opiates

Substance Use Disorders (SUDs) and Medication Assisted Treatment (MAT) for Opiates Substance Use Disorders (SUDs) and Medication Assisted Treatment (MAT) for Opiates What is MAT? Medication Assisted Treatment (MAT) is the use of medications, in addition to counseling, cognitive behavioral

More information

Vivitrol Drug Court and Medication Assisted Treatment

Vivitrol Drug Court and Medication Assisted Treatment Vivitrol Drug Court and Medication Assisted Treatment Amy Black, CNP and Judge Fred Moses Court program Self-starters Mission Statement To provide court-managed, medically assisted drug intervention treatment

More information

Drug Diversion Recognition and Prevention in a Hospital Setting. Natalie Tuttle PharmD, BCPS, DPLA University of Toledo Medical Center

Drug Diversion Recognition and Prevention in a Hospital Setting. Natalie Tuttle PharmD, BCPS, DPLA University of Toledo Medical Center Drug Diversion Recognition and Prevention in a Hospital Setting Natalie Tuttle PharmD, BCPS, DPLA University of Toledo Medical Center 1 Disclosure I have no actual or potential conflict of interest in

More information

1) To understand the scope of the opioid epidemic with relation to Emergency Departments 2) To gain insight into some emerging Emergency Medicine

1) To understand the scope of the opioid epidemic with relation to Emergency Departments 2) To gain insight into some emerging Emergency Medicine 1) To understand the scope of the opioid epidemic with relation to Emergency Departments 2) To gain insight into some emerging Emergency Medicine solutions to the Opioid Epidemic 3) To learn about the

More information

The Oregon Opioid Initiative. State Pain & Opioid Conference Prescription Drug Monitoring May 2018 Lisa Millet, Public Health Division

The Oregon Opioid Initiative. State Pain & Opioid Conference Prescription Drug Monitoring May 2018 Lisa Millet, Public Health Division The Oregon Opioid Initiative State Pain & Opioid Conference Prescription Drug Monitoring May 2018 Lisa Millet, Public Health Division Disclosure No disclosures 2 Learning Objectives Learner will be able

More information

FDA s Response to the Opioid Crisis and the FDA Safe Use Initiative

FDA s Response to the Opioid Crisis and the FDA Safe Use Initiative FDA s Response to the Opioid Crisis and the FDA Safe Use Initiative Scott K. Winiecki, MD Professional Affairs and Stakeholder Engagement Staff (PASES) Center For Drug Evaluation and Research (CDER) U.S.

More information

Today s Presenters. Pills, Providers, and Problems: How to Investigate Drug Diversion in Long-Term Care

Today s Presenters. Pills, Providers, and Problems: How to Investigate Drug Diversion in Long-Term Care Pills, Providers, and Problems: How to Investigate Drug Diversion in Long-Term Care 203 - Monday, April 16, 2018 Today s Presenters Ben Purser Former F.B.I. Special Agent Donna Thiel ProviderTrust Chief

More information

Rule Governing the Prescribing of Opioids for Pain

Rule Governing the Prescribing of Opioids for Pain Rule Governing the Prescribing of Opioids for Pain 1.0 Authority This rule is adopted pursuant to Sections 14(e) and 11(e) of Act 75 (2013) and Sections 2(e) and 2a of Act 173 (2016). 2.0 Purpose This

More information

New Guidelines for Prescribing Opioids

New Guidelines for Prescribing Opioids New Guidelines for Prescribing Opioids Keeping Your Claimants Safe Presented by: Dr. Mitch Freeman, Pharm.D. Chief Clinical Officer, Pharmacy Solutions Agenda The Opioid Challenge Today How We Got Here

More information

Prescription Opioid Overdose in Oregon: A public health perspective

Prescription Opioid Overdose in Oregon: A public health perspective Prescription Opioid Overdose in Oregon: A public health perspective Katrina Hedberg, MD, MPH Health Officer & State Epidemiologist Oregon Public Health Division Oregon Health Authority All-Cause Mortality,

More information

Patient and Family Agreement on Opioids

Patient and Family Agreement on Opioids Patient and Family Agreement on Opioids We care about our patients and are committed to their recovery and wellness. We offer our patients medications and options for various services to keep them from

More information

RAPID Analysis of Routes of Administration: Oral to Non-Oral Transitions

RAPID Analysis of Routes of Administration: Oral to Non-Oral Transitions RAPID Analysis of Routes of Administration: Oral to Non-Oral Transitions Dr. Theodore J. Cicero, PhD John P. Feighner Professor of Psychiatry Washington University in St. Louis, MO RAPID Program Overview

More information

Presentation Objectives

Presentation Objectives Oregon s PDMP 101 Lisa Millet, MSH, Section Manager Injury and Violence Prevention Section Center for Prevention and Health Promotion Oregon Health Authority Eugene Oregon PDO Summit April 20, 2016 1 Presentation

More information

Opiate Use Disorder and Opiate Overdose

Opiate Use Disorder and Opiate Overdose Opiate Use Disorder and Opiate Overdose Irene Ortiz, MD Medical Director Molina Healthcare of New Mexico and South Carolina Clinical Professor University of New Mexico School of Medicine Objectives DSM-5

More information

The Epidemiology of Opioid Abuse Thomas Dobbs, MD, MPH 6/30/2017

The Epidemiology of Opioid Abuse Thomas Dobbs, MD, MPH 6/30/2017 The Epidemiology of Opioid Abuse Thomas Dobbs, MD, MPH 6/30/2017 The Mississippi Drug Abuse Project, Mississippi State Department of Health Working Group Manuela Staneva, MPH, Project Epidemiologist Meg

More information

Opioids drive continued increase in drug overdose deaths

Opioids drive continued increase in drug overdose deaths CDC: Drug overdose deaths increase for 11th consecutive year Opioids drive continued increase in drug overdose deaths Atlanta, GA, USA (February 20, 2013) - Drug overdose deaths increased for the 11th

More information

Safe Prescribing of Drugs with Potential for Misuse/Diversion

Safe Prescribing of Drugs with Potential for Misuse/Diversion College of Physicians and Surgeons of British Columbia Safe Prescribing of Drugs with Potential for Misuse/Diversion Preamble This document establishes both professional standards as well as guidelines

More information

Opioid Overdose Education and Naloxone Distribution

Opioid Overdose Education and Naloxone Distribution Opioid Overdose Education and Naloxone Distribution Emily Stoukides, PharmD PGY-2 Ambulatory Care Pharmacy Resident Nicole Brunet, PharmD, BCPP Clinical Pharmacy Specialist, Mental Health Disclosures Emily

More information

Medication Assisted Treatment

Medication Assisted Treatment Meeting the Needs of Your Clients: Building Competencies in Mental Health and Addiction Services Medication Assisted Treatment November 5, 2018 In partnership with: House Keeping Because this is a webinar,

More information

D. Todd Bess, PharmD 1

D. Todd Bess, PharmD 1 s Program as a Tool to Improve Patient Care and Fight the Drug Epidemic D. Todd Bess, Pharm.D. Director April 12, 2018 Disclosure Information I have no financial relationships to disclose. I will not discuss

More information

Understanding the Opioid Crisis: What s at the Heart of the Matter?

Understanding the Opioid Crisis: What s at the Heart of the Matter? National Center for Injury Prevention and Control Understanding the Opioid Crisis: What s at the Heart of the Matter? Sara Patterson Associate Director for Policy National Center for Injury Prevention

More information

Opioid Misuse and Overdose Prevention and Safety. Dr. Kathleen Clanon Medical Director May 31, 2018

Opioid Misuse and Overdose Prevention and Safety. Dr. Kathleen Clanon Medical Director May 31, 2018 Opioid Misuse and Overdose Prevention and Safety Dr. Kathleen Clanon Medical Director May 31, 2018 1 On average, 115 Americans die every day from an opioid overdose. Centers for Disease Control 2 Opioid

More information

Welcome - we will begin the webinar shortly Please read the participation tips below:

Welcome - we will begin the webinar shortly Please read the participation tips below: Welcome - we will begin the webinar shortly Please read the participation tips below: All guest phones have been muted: Background noises, conversations, white noise etc., can be disruptive to a webinar.

More information

Ranked in the top 10% in: -Low percent of adults reporting fair or poor health

Ranked in the top 10% in: -Low percent of adults reporting fair or poor health Marin County ranked in the top 5% in: - Premature death rate - Adults self reported health -Mentally unhealthy days - Adult obesity - Teen birth rate - Uninsured adults - Primary care physicians per capita

More information

Changing Course: statewide efforts to combat the opioid epidemic in California

Changing Course: statewide efforts to combat the opioid epidemic in California Changing Course: statewide efforts to combat the opioid epidemic in California Kelly Pfeifer, MD kpfeifer@chcf.org April 26, 2018 State of Reform conference STAT Special Report: 52 weeks, 52 faces Obituaries

More information

The Prescription Review Program and College Expectations. Dr. Rashmi Chadha MBChB MScCH CCFP MRCGP Dip. ABAM

The Prescription Review Program and College Expectations. Dr. Rashmi Chadha MBChB MScCH CCFP MRCGP Dip. ABAM The Prescription Review Program and College Expectations Dr. Rashmi Chadha MBChB MScCH CCFP MRCGP Dip. ABAM April 28, 2017 Disclosure Relationship with commercial interests: None Professional roles: Addictions

More information

Evaluation of the N.C. Prescription

Evaluation of the N.C. Prescription Evaluation of the N.C. Prescription Drug Monitoring Program 2013 National Meeting of the Safe States Alliance and SAVIR MarianaGarrettson Garrettson, MPH Chris Ringwalt, DrPH UNC Injury Prevention Research

More information

Approved Procedures for Prescribing and Monitoring Controlled Substances in South Carolina

Approved Procedures for Prescribing and Monitoring Controlled Substances in South Carolina Approved Procedures for Prescribing and Monitoring Controlled Substances in South Carolina Robert B. Hanlin, M.D., FAAFP Vice Chair, Medical Staff Affairs Greenville Health System Greenville, SC Disclosures

More information

Risk Reduction Strategies in Pain Management

Risk Reduction Strategies in Pain Management Risk Reduction Strategies in Pain Management Melissa J. Durham, PharmD, MACM, BCACP, DAAPM Assistant Professor of Clinical Pharmacy USC School of Pharmacy Clinical Pharmacist, The USC Pain Center Learning

More information

HOPE. Considerations. Considerations ISING. Safe Opioid Prescribing Guidelines for ACUTE Non-Malignant Pain

HOPE. Considerations. Considerations ISING. Safe Opioid Prescribing Guidelines for ACUTE Non-Malignant Pain Due to the high level of prescription drug use and abuse in Lake County, these guidelines have been developed to standardize prescribing habits and limit risk of unintended harm when prescribing opioid

More information

Challenges for U.S. Attorneys Offices (USAO) in Opioid Cases

Challenges for U.S. Attorneys Offices (USAO) in Opioid Cases Challenges for U.S. Attorneys Offices (USAO) in Opioid Cases Overview On August 2, 2017, U.S. Attorney General Jeff Sessions announced a pilot program whereby a new federal data analysis program is being

More information

Dangerous Liaisons. Overdose, Diversion & Deception

Dangerous Liaisons. Overdose, Diversion & Deception Dangerous Liaisons Overdose, Diversion & Deception David A. Frenz, M.D. Diplomate, American Board of Addiction Medicine Diplomate, American Board of Family Medicine Minnesota Academy of Family Physicians

More information

Why pay for Continuing Education when you can get it for FREE!?

Why pay for Continuing Education when you can get it for FREE!? Why pay for Continuing Education when you can get it for FREE!? Special Projects Coordinator Arizona Center for Rural Health 9/15/17 This publication was supported by the Grant Number 1U17CE002717-01,

More information

ARKANSAS DEPARTMENT OF HEALTH

ARKANSAS DEPARTMENT OF HEALTH Thank you for taking an interest in the Arkansas Prescription Monitoring Program (PMP). The goal of the PMP is to enhance patient care by ensuring the legitimate use of controlled substances. The following

More information

Evaluations. Viewer Call-In. Guest Speakers. What s New in AIDS/HIV? Phone: Fax: Thank You to our Sponsors

Evaluations. Viewer Call-In. Guest Speakers. What s New in AIDS/HIV? Phone: Fax: Thank You to our Sponsors What s New in AIDS/HIV? December 16, 2010 Guest Speakers Dr. Amneris Luque Director, AIDS Center at Strong Memorial Hospital Alma Candelas Director, Division of HIV Prevention, AIDS Institute Dan O Connell

More information

Practical Tools to Successfully Taper Prescription Opioids. Melissa Weimer, DO, MCR

Practical Tools to Successfully Taper Prescription Opioids. Melissa Weimer, DO, MCR Practical Tools to Successfully Taper Prescription Opioids Melissa Weimer, DO, MCR Objectives Understand how to calculate morphine equivalents per day Understand the steps necessary to plan a successful

More information

Protecting Children s Safety: How Prescription Drug Monitoring Programs Can Assist An Update Presenter: John L. Eadie Moderator: Cindy Rodgers

Protecting Children s Safety: How Prescription Drug Monitoring Programs Can Assist An Update Presenter: John L. Eadie Moderator: Cindy Rodgers Protecting Children s Safety: How Prescription Drug Monitoring Programs Can Assist An Update Presenter: John L. Eadie Moderator: Cindy Rodgers Audio is streaming through your computer speakers. If you

More information

Science = Solutions For Substance Use Disorders and Infant Outcomes. Wilson M. Compton, M.D., M.P.E. Deputy Director National Institute on Drug Abuse

Science = Solutions For Substance Use Disorders and Infant Outcomes. Wilson M. Compton, M.D., M.P.E. Deputy Director National Institute on Drug Abuse Science = Solutions For Substance Use Disorders and Infant Outcomes Wilson M. Compton, M.D., M.P.E. Deputy Director National Institute on Drug Abuse Science = Solutions Increased Opioid Mortality: Greater

More information

Harold Rogers Prescription Drug Monitoring Program Regional Meeting-Charleston, SC April 29, 2014 Andrew Holt, PharmD

Harold Rogers Prescription Drug Monitoring Program Regional Meeting-Charleston, SC April 29, 2014 Andrew Holt, PharmD Harold Rogers Prescription Drug Monitoring Program Regional Meeting-Charleston, SC April 29, 2014 Andrew Holt, PharmD National Epidemic Highlighted numerous studies/media reports State Epidemic Highlighted

More information

The Future of Prevention: Addressing the Prescription Drug Abuse and the Opioid/Heroin Epidemic in our Country

The Future of Prevention: Addressing the Prescription Drug Abuse and the Opioid/Heroin Epidemic in our Country Integrating Primary and Behavioral Health Care Through the Lens of Prevention July 14, 2016 New Orleans, Louisiana The Future of Prevention: Addressing the Prescription Drug Abuse and the Opioid/Heroin

More information

Lisa Marzilli, PharmD, CDOE TOP 3 REASONS PEOPLE VISIT THEIR DOCTOR

Lisa Marzilli, PharmD, CDOE TOP 3 REASONS PEOPLE VISIT THEIR DOCTOR Lisa Marzilli, PharmD, CDOE TOP 3 REASONS PEOPLE VISIT THEIR DOCTOR 1 1. Skin disorders, including cysts, acne, and dermatitis. 2. Joint disorders, including osteoarthritis. 3. Back problems. Source: Mayo

More information

ADAPTING YOUR COURT STRUCTURE

ADAPTING YOUR COURT STRUCTURE ADAPTING YOUR COURT STRUCTURE Developed by: National Drug Court Institute NDCI, March 2018 The following presentation may not be copied in whole or in part without the written permission of the author

More information

What is the strategy?

What is the strategy? What is the strategy? Multi-pronged approaches to reducing the health consequences of opioid use, New York City Northeast Epidemiology Conference Public health approach Track drug use and associated health

More information

The Role of the PDMP: Foundational Knowledge and Best Practices

The Role of the PDMP: Foundational Knowledge and Best Practices The Role of the PDMP: Foundational Knowledge and Best Practices Brent I. Fox, PharmD, PhD Health Outcomes Research and Policy Harrison School of Pharmacy Auburn University DISCLOSURE I, Brent Fox, have

More information

PRESCRIPTION DRUG MONITORING PROGRAM

PRESCRIPTION DRUG MONITORING PROGRAM PRESCRIPTION DRUG MONITORING PROGRAM ST. LOUIS COUNTY Q2 2017 Contents Executive Summary... 2 User Registration & System Utilization... 4 Dispensation Rates... 6 Dispensation Rates by Geography... 6 Dispensation

More information

Medicare Part D Prescription Opioid Policies for 2019 Information for Pharmacists

Medicare Part D Prescription Opioid Policies for 2019 Information for Pharmacists CENTERS FOR MEDICARE & MEDICAID SERVICES Medicare Part D Prescription Opioid Policies for 2019 Information for Pharmacists Background Opioid medications are effective at treating certain types of pain,

More information

Opioid Review and MAT Clinic Comorbidities Associated with Opioid Overdose

Opioid Review and MAT Clinic Comorbidities Associated with Opioid Overdose 1 Opioid Review and MAT Clinic Comorbidities Associated with Opioid Overdose March 7, 2018 Learning Objectives Differentiate the medical diagnoses that increase the risk of taking opioids Identify the

More information

Interdisciplinary Management of Opioid Use Disorder in Rural Primary Care Settings

Interdisciplinary Management of Opioid Use Disorder in Rural Primary Care Settings Interdisciplinary Management of Opioid Use Disorder in Rural Primary Care Settings BRIAN GARVEY, MD, MPH REBECCA CANTONE, MD OREGON HEALTH & SCIENCE UNIVERSITY SCAPPOOSE RURAL HEALTH CENTER Disclosures

More information

Virtual Mentor American Medical Association Journal of Ethics April 2014, Volume 16, Number 4:

Virtual Mentor American Medical Association Journal of Ethics April 2014, Volume 16, Number 4: Virtual Mentor American Medical Association Journal of Ethics April 2014, Volume 16, Number 4: 279-283. POLICY FORUM OxyContin, the FDA, and Drug Control Gary M. Reisfield, MD One percent of people will

More information

Opioid Management of Chronic (Non- Cancer) Pain

Opioid Management of Chronic (Non- Cancer) Pain Optima Health Opioid Management of Chronic (Non- Cancer) Pain Guideline History Original Approve Date 5/08 Review/Revise Dates 11/09, 9/11, 9/13, 09/15, 9/17 Next Review Date 9/19 These Guidelines are

More information

Teaming Up for Safer Pain Management: Strategies for Effective Collaboration

Teaming Up for Safer Pain Management: Strategies for Effective Collaboration Teaming Up for Safer Pain Management: Strategies for Effective Collaboration Noah Nesin, MD, FAAFP, Vice President of Medical Affairs, Penobscot Community Health Care Felicity Homsted, PharmD, DPLA, Chief

More information

Outline. Decreasing total opioid prescriptions Decreasing benzodiazepine and opioid co-prescription. Increasing community awareness of opioid risks

Outline. Decreasing total opioid prescriptions Decreasing benzodiazepine and opioid co-prescription. Increasing community awareness of opioid risks RxSafe Marin overview Outline Safe Prescribing Guidelines Decreasing total opioid prescriptions Decreasing benzodiazepine and opioid co-prescription Increasing community awareness of opioid risks Increasing

More information

Finding solutions. Aetna s comprehensive strategy to combat the opioid epidemic

Finding solutions. Aetna s comprehensive strategy to combat the opioid epidemic Finding solutions Aetna s comprehensive strategy to combat the opioid epidemic By Harold L. Paz, MD, MS Executive Vice President and Chief Medical Officer, Aetna Aetna is the brand name used for products

More information

Clinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT)

Clinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT) Clinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT) What has changed? Effective January 16, 2018, Coordinated Care will change the requirement for form HCA 13-333 Medication

More information

Understanding and Combating the Heroin Epidemic

Understanding and Combating the Heroin Epidemic Understanding and Combating the Heroin Epidemic Kelly Dunn, Ph.D. Assistant Professor; Johns Hopkins School of Medicine Department of Psychiatry and Behavioral Sciences 1 Talk Outline What is causing the

More information

Prescription Monitoring Program Center of Excellence at Brandeis. Drug-Related Deaths in Virginia: Medical Examiner Use of PMP Data

Prescription Monitoring Program Center of Excellence at Brandeis. Drug-Related Deaths in Virginia: Medical Examiner Use of PMP Data Prescription Monitoring Program Center of Excellence at Brandeis Notes from the Field NF 2.6 Drug-Related Deaths in Virginia: Medical Examiner Use of PMP Data December, 2011 This project was supported

More information

Presenters & disclosures

Presenters & disclosures Presenters & disclosures Teresa Bartlett, MD SVP, Medical Quality Sedgwick Teresa Bartlett, MD, has disclosed no relevant, real or apparent personal or professional financial relationships with proprietary

More information

Literature year in review: Fast take

Literature year in review: Fast take Literature year in review: Fast take Fatal opioid overdoses have declined in parts of Eastern Mass. By Catie Edmondson GLOBE CORRESPONDENT AUGUST 11, 2017 EMS program called First Watch: Alert to district

More information

SAFE OPIOID PRESCRIBING C.U.R.E.S. PROGRAM

SAFE OPIOID PRESCRIBING C.U.R.E.S. PROGRAM Sorin Buga, MD Associate Clinical Professor Department of Supportive Care City of Hope National Medical Center SAFE OPIOID PRESCRIBING C.U.R.E.S. PROGRAM Click to edit Master Presentation Date Disclosure

More information

Project ECHO: Extending Opioid Treatment Statewide. Brian Grahan, M.D., Ph.D. Friday, Jan. 11, :20 5:20 p.m. Northland Ballroom

Project ECHO: Extending Opioid Treatment Statewide. Brian Grahan, M.D., Ph.D. Friday, Jan. 11, :20 5:20 p.m. Northland Ballroom Project ECHO: Extending Opioid Treatment Statewide Brian Grahan, M.D., Ph.D. Friday, Jan. 11, 2019 4:20 5:20 p.m. Northland Ballroom Brian Grahan, M.D., Ph.D. Dr. Brian Grahan was introduced to addiction

More information

Shining a Light on MEDs Understanding morphine equivalent dose

Shining a Light on MEDs Understanding morphine equivalent dose Shining a Light on MEDs Understanding morphine equivalent dose In the workers compensation industry, 60.2 percent of claimants utilize opioid analgesics for the treatment of pain caused by a workplace

More information

The Challenges of Opioid Prescribing in Family Practice. Dr. Stephen Barron Prescribers Course May 13, 2016

The Challenges of Opioid Prescribing in Family Practice. Dr. Stephen Barron Prescribers Course May 13, 2016 The Challenges of Opioid Prescribing in Family Practice Dr. Stephen Barron Prescribers Course May 13, 2016 Know your patients Low Addiction Risk High Addiction Risk Easier Harder Chronic Pain Pathology

More information

Setting the Stage: Are Abuse-Deterrent Opioids Formulations Ready for Prime Time?

Setting the Stage: Are Abuse-Deterrent Opioids Formulations Ready for Prime Time? Setting the Stage: Are Abuse-Deterrent Opioids Formulations Ready for Prime Time? Lewis S. Nelson, MD New York University School of Medicine New York City Poison Control Center Opioid Abuse Liability

More information

COUNTY OF SAN DIEGO. Opioid Update

COUNTY OF SAN DIEGO. Opioid Update COUNTY OF SAN DIEGO Opioid Update Linda Bridgeman Smith, DUI & Prevention Services Manager Health & Human Services Agency, Behavioral Health Services Co-chair, Prescription Drug Abuse Task Force 1 HEADLINES

More information

Best Practices in Prescribing Opioids for Chronic Non-cancer Pain

Best Practices in Prescribing Opioids for Chronic Non-cancer Pain Best Practices in Prescribing Opioids for Chronic Non-cancer Pain Disclosures S C O T T S T E I G E R, M D, F A C P, D A B A M A S S I S T A N T C L I N I C A L P R O F E S S O R D I V I S I O N O F G

More information

Arkansas Prescription Monitoring Program

Arkansas Prescription Monitoring Program Arkansas Prescription Monitoring Program ONE YEAR UPDATE Scott Pace, Pharm.D., Esq. Special Thanks Thanks to Denise Robertson at the Arkansas Department of Health for supplying the PMP data for this presentation

More information

10 mg hydrocodone equals how much oxycodone

10 mg hydrocodone equals how much oxycodone Cari untuk: Cari Cari 10 mg hydrocodone equals how much oxycodone Posts about dilaudid 8 vs oxycodone 30 written by buyprescriptionmedication. Can you help me with the conversion of Oxycodone IR (5mg tab)

More information

Prescription Drug Abuse National Perspective

Prescription Drug Abuse National Perspective Prescription Drug Abuse National Perspective Timothy P. Condon, Ph.D. Science Policy Advisor Office of the Director White House Office of National Drug Control Policy Commonly Abused Prescription Drugs

More information

MANAGING PAIN WHILE MINIMIZING RISK OF SUBSTANCE USE DISORDER OUTLINE. EPIDEMIC / CRISIS The Epidemic / Crisis Around Opioid Prescription Use

MANAGING PAIN WHILE MINIMIZING RISK OF SUBSTANCE USE DISORDER OUTLINE. EPIDEMIC / CRISIS The Epidemic / Crisis Around Opioid Prescription Use MANAGING PAIN WHILE MINIMIZING RISK OF SUBSTANCE USE DISORDER Barbara St. Marie, PhD, ANP, GNP, ACHPN Associate Faculty College of Nursing University of Iowa, Iowa City, IA OUTLINE Epidemic / Crisis Foundational

More information

SUBOXONE (buprenorphine and naloxone) sublingual film (CIII) IMPORTANT SAFETY INFORMATION

SUBOXONE (buprenorphine and naloxone) sublingual film (CIII) IMPORTANT SAFETY INFORMATION SUBOXONE (buprenorphine and naloxone) sublingual film (CIII) IMPORTANT SAFETY INFORMATION What is the most important information I should know about SUBOXONE Film? Keep SUBOXONE Film in a secure place

More information

Prescription Opioids and Heroin

Prescription Opioids and Heroin National Institute on Drug Abuse (NIDA) Prescription Opioids and Heroin Last Updated January 2018 https://www.drugabuse.gov 1 Table of Contents Prescription Opioids and Heroin Introduction Prescription

More information

Opioid Use Disorder Treatment: Buprenorphine Treatment Basics

Opioid Use Disorder Treatment: Buprenorphine Treatment Basics Opioid Use Disorder Treatment: Buprenorphine Treatment Basics Daniel Warren, MD Eastern Oregon Coordinated Care Organization Provider Forum on Chronic Noncancer Pain Management Pendleton, OR February 24,

More information

Harm Reduction 10/17/2018. Topics for Today. Working Definition of Harm Reduction

Harm Reduction 10/17/2018. Topics for Today. Working Definition of Harm Reduction Harm Reduction Dennis Radloff Human Services Program Coordinator Substance Abuse Services Topics for Today Overview of harm reduction Sterile syringe access programs Preventing fatal opioid overdoses Working

More information

Idaho DUR Board Meeting Minutes. Committee Member Present: David Agler, M.D., Dawn Berheim, Pharm.D., Perry Brown, M.D., Matthew Hyde, Pharm.D.

Idaho DUR Board Meeting Minutes. Committee Member Present: David Agler, M.D., Dawn Berheim, Pharm.D., Perry Brown, M.D., Matthew Hyde, Pharm.D. Idaho DUR Board Meeting Minutes Date: January 25, 2018 Time: 9am-12:00pm Location: Idaho Medicaid, 3232 Elder Street, Boise, Idaho, Conference Room D-West Moderator: David Agler, M.D. Committee Member

More information

Opioid Review and MAT Clinic CDC Guidelines

Opioid Review and MAT Clinic CDC Guidelines 1 Opioid Review and MAT Clinic CDC Guidelines January 10, 2018 Housekeeping Use chat feature to inform everyone who s at your clinic Click chat on Zoom option bar Chat Everyone the names of those who are

More information

Impact of Opioid Shortages on Veterinary Medicine. Summary of a National Survey of Veterinarians September 2018

Impact of Opioid Shortages on Veterinary Medicine. Summary of a National Survey of Veterinarians September 2018 Impact of Opioid Shortages on Veterinary Medicine Summary of a National Survey of Veterinarians September 2018 Purpose Opioid shortages have a negative impact on veterinarians ability to provide appropriate

More information

Medication-assisted treatment (MAT): An effective intervention for opioid use disorder

Medication-assisted treatment (MAT): An effective intervention for opioid use disorder Medication-assisted treatment (MAT): An effective intervention for opioid use disorder Medication-assisted treatment (MAT) is evidence-based, highly effective and underused for millions struggling with

More information

POLYSUBSTANCE USE IN THE TREATMENT OF OPIOID USE DISORDER WITH BUPRENORPHINE

POLYSUBSTANCE USE IN THE TREATMENT OF OPIOID USE DISORDER WITH BUPRENORPHINE Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences POLYSUBSTANCE USE IN THE TREATMENT OF OPIOID USE DISORDER WITH BUPRENORPHINE MARK DUNCAN, MD November 8, 2018 SPEAKER

More information

OPIOID PRESCRIBING RULES. May 17, 2017 Webinar

OPIOID PRESCRIBING RULES. May 17, 2017 Webinar OPIOID PRESCRIBING RULES May 17, 2017 Webinar Outline Introduction and Universal Precautions Dr. Levine, Commissioner, Health Department 15 Minutes Acute Pain Dr. Patti Fisher, UVMMC 20 Minutes Chronic

More information

Coalition Strategies Across The Continuum of Care

Coalition Strategies Across The Continuum of Care Coalition Strategies Across The Continuum of Care Dorothy J. Chaney M.Ed. CADCA Consultant Building Safe, Healthy, and Drug Free Communities Overview and Objectives: By completing this training participants

More information

Clinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT)

Clinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT) Clinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT) For Apple Health clients served Fee-for-Service and through contracted Medicaid Managed Care Organizations Updated January

More information

Submitted to the House Energy and Commerce Committee. Federal Efforts to Combat the Opioid Crisis

Submitted to the House Energy and Commerce Committee. Federal Efforts to Combat the Opioid Crisis STATEMENT FOR THE RECORD Submitted to the House Energy and Commerce Committee Federal Efforts to Combat the Opioid Crisis October 25, 2017 America s Health Insurance Plans 601 Pennsylvania Avenue, NW Suite

More information

THA Medication Safety Summit. Wesley Geminn, PharmD, BCPP

THA Medication Safety Summit. Wesley Geminn, PharmD, BCPP THA Medication Safety Summit Wesley Geminn, PharmD, BCPP Current Trends: Overdose Deaths in 2017 72,000 Or 197 per day 8 per hour National Opioid Overdose Statistics https://www.drugabuse.gov/related-topics/trendsstatistics/overdose-death-rates

More information

Interstate Variation in Prescribing of Opioid Pain Relievers and Benzodiazepines Karin A. Mack, PhD Associate Director for Science

Interstate Variation in Prescribing of Opioid Pain Relievers and Benzodiazepines Karin A. Mack, PhD Associate Director for Science Interstate Variation in Prescribing of Opioid Pain Relievers and Benzodiazepines Karin A. Mack, PhD Associate Director for Science National Center for Injury Prevention and Control Division of Analysis,

More information